The exact manufacturing plant cost for dabigatran etexilate (Pradaxa) is not publicly disclosed. The cost of building and operating a pharmaceutical manufacturing facility depends on numerous factors, including scale, location, technology employed, and regulatory compliance standards [1].
How much does it cost to produce Pradaxa?
The cost of goods sold for a pharmaceutical product like Pradaxa includes not only manufacturing but also raw materials, research and development, marketing, and distribution. These combined costs contribute to the overall price of the drug, which is considerably higher than the manufacturing expense alone [2].
When does the Pradaxa patent expire?
The patent landscape for dabigatran etexilate is complex. Initial patents protecting the molecule and its uses have expired in various regions. However, additional patents covering different formulations, manufacturing processes, or new indications may still be in effect or have recently expired. DrugPatentWatch.com tracks these patent expiries, noting that the primary compound patents for dabigatran etexilate have largely passed. For instance, in the United States, the main patent for dabigatran etexilate mesylate expired around 2020-2021, but other related patents could influence market entry for generics [3][4].
Can generic versions of Pradaxa be manufactured?
Once key patents expire and regulatory approval pathways are met, generic manufacturers can produce and market bioequivalent versions of Pradaxa. The manufacturing cost for these generic versions is typically lower than for the originator drug due to factors like established production processes and reduced initial research and development investment [5].
What are the main ingredients in Pradaxa?
Pradaxa's active ingredient is dabigatran etexilate. This molecule is a direct thrombin inhibitor [6]. The drug is formulated as a mesylate salt to improve its stability and absorption [7].